儿童银屑病患者生活质量与严重程度及范围改善的关联
该单中心队列研究基于Child-CAPTURE注册数据,纳入319例儿童银屑病患者,分析PASI和BSA改善程度与CDLQI变化的关系。结果显示PASI≥90和BSA≥90应答类别CDLQI改善最大,全身治疗较外用治疗CDLQI改善更显著,独立于PASI应答。
要点
- PASI≥90或BSA下降≥90%与儿童银屑病生活质量最大改善相关。
- 全身治疗较外用治疗带来更大的CDLQI改善,独立于PASI应答。
- 达到PASI≥90和BSA下降≥90%可能是临床有意义的治疗目标。
核心结论
- 在真实世界儿童银屑病队列中,PASI≥90、BSA下降≥90%及全身治疗与生活质量最大改善相关。
研究设计与样本
- 单中心前瞻性观察性队列研究,数据来自Child-CAPTURE注册,纳入2008年9月3日至2018年5月4日期间年龄<18岁的银屑病患儿。
- 共分析319例患者(中位年龄10.0岁,IQR 7.0;女性183例,57.4%),PASI改善分析含399个治疗 episode,BSA改善分析含366个治疗 episode。
主要发现
- PASI≥90应答类别CDLQI评分估计边际均值变化为-6.6(95% CI,-7.5至-5.7),为各PASI类别中改善最大。
- BSA≥90应答类别CDLQI评分估计边际均值变化为-6.8(95% CI,-7.5至-6.1),为各BSA类别中改善最大。
- 全身治疗相比外用治疗显示更大程度的CDLQI改善,独立于PASI应答类别。
关键数值与推荐
- PASI应答分类:0至<50、50至<75、75至<90、≥90。
- BSA应答分类:0至<50、50至<75、75至<90、≥90。
- 治疗类别聚类为外用、地蒽酚、传统系统性、生物制剂;UV-B光疗因数量少未评估。
临床怎么用
- 儿童银屑病治疗可考虑以PASI≥90和BSA下降≥90%作为追求最佳生活质量的临床目标。
- 全身治疗可能较外用治疗带来额外的生活质量获益,选择方案时可综合评估。
局限性
- 单中心真实世界队列设计,结果外推需谨慎。
- UV-B光疗因样本量少未纳入评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Treatment of psoriasis is associated with improved quality of life (QOL) in those with the disease. However, in daily clinical practice, the association between the degree of psoriasis clearance and QOL has not been studied to date, especially in the pediatric population. OBJECTIVES: To identify the association between the degree of psoriasis improvement (as measured by the Psoriasis Area Severity Index [PASI] and body surface area [BSA] response) and QOL (as measured by the Children's Dermatology Life Quality Index [CDLQI]) in pediatric psoriasis, and to assess the association of treatment type with QOL, independent of psoriasis improvement. DESIGN, SETTING, AND PARTICIPANTS: Data used in this single-center cohort study were extracted from the Child-CAPTURE (Continuous Assessment of Psoriasis Treatment Use Registry), a prospective, observational, daily clinical practice cohort of all children (aged <18 years) with a psoriasis diagnosis who attended the outpatient clinic of the Department of Dermatology at the Radboud University Medical Center in Nijmegen, the Netherlands, between September 3, 2008, and May 4, 2018. All records of treatment episodes with CDLQI, PASI, and BSA scores were included in the analysis. EXPOSURES: Patients were treated according to daily clinical care. Treatments were clustered into topical, dithranol, conventional systemic, and biological treatments. Because of low numbers of UV-B phototherapy, this treatment was not assessed. MAIN OUTCOMES AND MEASURES: Primary outcomes were mean change of CDLQI scores per PASI and BSA response categories (0 to <50, 50 to <75, 75 to <90, and ≥90) and mean CDLQI change per treatment categories. RESULTS: In total, 319 patients (median [interquartile range] age, 10.0 [7.0] years; 183 female [57.4%]) were analyzed for PASI score improvement (399 treatment episodes) and improvement in BSA involvement (366 treatment episodes). The greatest improvements in CDLQI scores were seen in the PASI ≥90 response category, with an estimated marginal mean change in CDLQI score of -6.6 (95% CI, -7.5 to -5.7). The greatest improvements in CDLQI scores were also observed in the BSA ≥90 response category, with an estimated marginal mean change in CDLQI score of -6.8 (95% CI, -7.5 to -6.1). Systemic treatment demonstrated a greater degree of improvement of CDLQI compared with topical treatment, independent of PASI response categories. CONCLUSIONS AND RELEVANCE: This cohort study in a real-world setting found that the greatest improvements in QOL were associated with PASI 90 or greater, a decrease in BSA involvement of 90% or greater, and systemic treatments. These findings suggest that reaching PASI 90 or greater and decreasing BSA involvement by at least 90% may be clinically meaningful treatment goals that will help pediatric patients with psoriasis reach optimal QOL.
引用
- Bruins FM, Bronckers IMGJ, Groenewoud HMM, et al. Association Between Quality of Life and Improvement in Psoriasis Severity and Extent in Pediatric Patients. JAMA Dermatol. 2020. PMID: 31774449. doi:10.1001/jamadermatol.2019.3717
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。